This book provides a systematic review of the development, function, and patho-physiologic role of plasmacytoid dendritic cells (pDCs) in humans. The chapters of the book discuss the origin and discovery, hematopoietic development as well as molecular regulation of pDCs in the context of immune activation as well as immune tolerance. It also discusses the role of pDCs in human diseases, including infections, autoimmune/inflammatory diseases, cancers and metabolic disorders, and opportunities for pDC‐targeting therapies in these varied clinical contexts.
Author(s): Dipyaman Ganguly
Publisher: Springer
Year: 2022
Language: English
Pages: 169
City: Cham
Preface
Contents
Chapter 1: Discovery of a New Dendritic Cell Subset
1.1 A Brief Biosketch of the Immune System
1.2 Discovery of the Conventional Dendritic Cells
1.3 The Search for a Professional Interferon Producer
1.4 A New Dendritic Cell Subset Is the ``Professional Interferon Producer´´
1.5 Conclusion
References
Chapter 2: Origin and Transcriptional Identity of Plasmacytoid Dendritic Cells
2.1 FLT3-Receptor Dependence and Shared Origin of cDCs and pDCs
2.2 Myeloid Versus Lymphoid Origin of pDCs
2.3 Transcriptional Program for pDC Commitment and Function
2.3.1 E2-2
2.3.2 IRF8
2.3.3 Regulators of Functional Identity
2.4 Localization and Migration of pDCs
2.5 Conclusions
References
Chapter 3: Activation and Functions of Plasmacytoid Dendritic Cells
3.1 Toll-like Receptor Activation and Signaling in pDCs
3.2 Cell Biology of Endosomal TLR Localization in pDCs
3.3 The Cytokine Response in pDCs in Response to TLR Activation
3.4 Antigen Presentation by pDCs
3.5 Cell Biology of Differential pDC Response to TLR Activation
3.6 Cellular Metabolism of Activated pDCs
3.7 The Elusive Role of IL-3 in pDC Immunobiology
3.8 Functional Heterogeneity of Plasmacytoid Dendritic Cells
3.9 Regulators of Type I IFN Induction by pDCs
3.9.1 ILT7
3.9.2 BDCA2
3.9.3 Siglec-H
3.10 Other Regulatory Surface Molecules in pDCs
3.11 Endocannabinoids and Cannabinoid Receptors
3.12 Metabolite Transporters and Receptors
3.13 Effect of Biological Sex on pDC Activation
3.14 Conclusions
References
Chapter 4: Plasmacytoid Dendritic Cells and Infections
4.1 RNA Viruses and pDCs
4.2 Human Immunodeficiency Virus and pDCs
4.3 PDCs and the Novel Coronavirus SARS-CoV-2
4.4 DNA Viruses and pDCs
4.5 PDCs in Bacterial Infections
4.5.1 Extracellular Bacteria and pDCs
4.5.2 Intracellular Bacteria and pDCs
4.6 PDCs in Malaria
4.7 PDCs in Fungal Infections
4.8 Conclusions
References
Chapter 5: Plasmacytoid Dendritic Cells in Autoimmunity
5.1 Systemic Lupus Erythematosus
5.2 Psoriasis
5.3 Systemic Sclerosis
5.4 Sjogren´s Syndrome
5.5 Role of pDCs in Other Major Rheumatological Disorders
5.6 Conclusions
References
Chapter 6: Plasmacytoid Dendritic Cells and Metabolic Disorders
6.1 Type 1 Diabetes Mellitus
6.2 Obesity and Type 2 Diabetes
6.3 Cardiovascular Components of Metabolic Syndrome
6.4 Fatty Liver Disease and Hepatic Metaflammation
6.5 A Potential Pathogenic Continuum for Autoimmune Diseases and Metabolic Syndrome
6.6 Conclusions
References
Chapter 7: Tolerogenic Functions of Plasmacytoid Dendritic Cells
7.1 Thymic pDCs and Central Tolerance
7.2 Mucosal Tolerance Driven by pDCs
7.3 Tolerogenic pDCs and Tissue Transplantation
7.4 Suppression of Anti-cancer Immunity
7.5 Conclusions
References
Chapter 8: Plasmacytoid Dendritic Cells and Cancer
8.1 Plasmacytoid Dendritic Cells and the ``Cancer-immunity Cycle´´
8.2 Leukemogenesis and pDCs
8.3 Breast Cancer and pDCs
8.4 Ovarian Carcinoma and pDCs
8.5 PDCs in Neoplasmas of the Aero-digestive Tract
8.6 Malignant Melanoma and pDCs
8.7 Conclusion
References
Chapter 9: Therapeutic Targeting of Plasmacytoid Dendritic Cells
9.1 Targeting pDCs and Type I IFNs in Autoreactive Inflammation
9.1.1 Targeting Endosomal TLRs in pDCs
9.1.2 Biologics Targeting pDCs and Type I IFNs
9.2 Targeting pDCs in Infection
9.3 Targeting pDCs in Cancer
9.3.1 Targeting Endosomal TLRs and Other pDC-intrinsic Molecules
9.3.2 PDC-Based Vaccines for Cancer
9.4 Conclusion
References
Abbreviations
